ClinicalTrials.gg
RecruitingNCT07888569Updated Nov 6, 2026

Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21)

A Phase 1 interventional study of DZD8586 and Rabeprazole in Healthy, sponsored by Dizal Pharmaceuticals. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Dizal Pharmaceuticals · Phase 1, Interventional, and Treatment

Updated Nov 6, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study is a phase 1, open-label, three-period crossover study to evaluate the effect of Rabeprazole, a proton pump inhibitor, on the pharmacokinetics of DZD8586 (Birelentinib) under fasted and fed conditions in healthy participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Dizal Pharmaceuticals is the lead sponsor of 39 studies on the registry; 15 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be able to understand the nature of the trial and provide a signed and dated, written form before any study-specific procedures, sampling, and analyses.
  2. Female and/or male aged 18 \~ 45 years (inclusive), at the time of signing the informed consent.
  3. (BMI) 18\~ 30 kg/m\^2. Bodyweight of ≥ 45 kg (Female) or ≥ 55 kg (Male).
  4. Non-smoker (never smoked or > 1 year from the last occurrence of smoking).
  5. Participants are healthy as determined by vital signs, physical examination, clinical laboratory tests, 12-lead , , , , TB, performed before the first administration of the study drug, including the following criteria.

    • (ALT) and aspartate aminotransferase (AST) \< (Upper Limit of Normal); Total \< ULN.
    • ≥ 90 mL/min or ≥ 90 mL/min/1.73m\^2.
  6. Male participants must be surgically sterile or using an acceptable method of during the study (from the time they sign consent) and for 30 days after the last dose of the Product to prevent pregnancy with a partner. Abstinence is an acceptable form of contraception, provided that the participant agrees to use barrier methods in conjunction with spermicides if they do engage in sexual intercourse.
  7. Female participants must have negative pregnancy tests at screening and check-in AND: have been surgically sterile OR and serum estradiol at screening OR, if of , must be using an acceptable method of contraception for the last three months. All females must agree to continue using their contraceptive method throughout the study period and for 30 days after the last dose of investigational product.

Exclusion criteria

Exclusion Criteria:

  1. Any condition which in the opinion of the investigator would interfere with the participant's ability to provide , comply with study instructions, confound interpretation of study results, or endanger the participant if he or she takes part in the trial.
  2. Reported history or any abnormalities at the screening of cardiac, hepatic, renal, respiratory, GI, endocrine, immunological, dermatological, hematological, neurological, or psychiatrical disease.
  3. Any cardiovascular abnormity or bleeding disorder. For example, during the screening period, the average resting corrected interval (QTC) on the (ECG) was > 450 msec for male and female.
  4. Any infectious diseases.
  5. History of of any type, except the following: surgically excised non-melanomatous skin cancers more than 5 years before receiving the Product.
  6. Patients who are allergic to or expected to be intolerant to DZD8586, rabeprazole and .
  7. Any of the following medical conditions:

    • Underwent any major surgery within 4 weeks prior to screening.
    • Has donated blood (including blood products) or experienced loss of blood ≥ 500 mL within 2 months before screening.
    • Has intractable nausea, vomiting, or chronic gastrointestinal disease.
    • Has a history of severe allergic or reaction; or is currently experiencing an allergic or hypersensitivity reaction.
  8. Have previously completed or withdrawn from this study or any other study investigating DZD8586 and have previously received DZD8586.
  9. Involvement in the planning and/or conduct of the study (applies to both Dizal staff and/or staff at the study site).
  10. For women only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding.
  11. Patients who have special dietary requirements and cannot accept the standard diet.
  12. Patients who cannot tolerate venipuncture or have a history of needle phobia or blood phobia.
  13. Any alcohol consumption or drug abuse.
  14. Participation in another clinical study with an investigational product administered in the last 28 days.
  15. Received a live or within 3 months before the first dose of the Investigational Product.
  16. Any of the foods, drugs, or products that may affect or potentially affect the investigational drug has been taken before screening or investigational product administration.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Single oral dose of DZD8586

    Each participant will receive three single doses of DZD8586 without food, with rabeprazole (with food) and with rabeprazole (without food).

    Drug: DZD8586 · Drug: Rabeprazole

Interventions

  • DZD8586 administered by mouth as a single dose in Period 1 (without food), Period 2 (with rabeprazole with food) and Period 3 (with rabeprazole without food).

  • Rabeprazole administered by mouth once a day for 7 days in Period 2 and 7 days in Period 3.

06

What researchers measure

Primary outcomes

  1. AUC0-inf of DZD8586

    area under plasma concentration-time profile from time 0 extrapolated to infinite time for DZD8586

    Time frame: Up to 120 hours post-dose

  2. AUC0-t of DZD8586

    area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration for DZD8586

    Time frame: Up to 120 hours post-dose

  3. Cmax of DZD8586

    observed maximal plasma DZD8586 concentration

    Time frame: Up to 120 hours post-dose

Secondary outcomes

  1. tmax of DZD8586 and DZ4581

    time to the plasma maximal concentration for DZD8586 and its metabolite DZ4581

    Time frame: Up to 120 hours post-dose

  2. CL/F of DZD8586

    apparent clearance for DZD8586

    Time frame: Up to 120 hours post-dose

  3. t1/2 of DZD8586 and DZ4581

    plasma terminal half-life for DZD8586 and its metabolite DZ4581

    Time frame: Up to 120 hours post-dose

  4. AUC0-inf of DZ4581

    area under plasma concentration-time profile from time 0 extrapolated to infinite time for DZ4581

    Time frame: Up to 120 hours post-dose

  5. AUC0-t of DZ4581

    area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration for DZ4581

    Time frame: Up to 120 hours post-dose

  6. Cmax of DZ4581

    observed maximal plasma DZ4581 concentration

    Time frame: Up to 120 hours post-dose

  7. AUC ratios of DZ4581 to DZD8586 (MRAUC)

    Time frame: Up to 120 hours post-dose

  8. Cmax ratios of DZ4581 to DZD8586 (MRCmax)

    Time frame: Up to 120 hours post-dose

  9. Number and percentage of participants with treatment-emergent adverse events (TEAEs) graded by CTCAE v5.0.

    To assess TEAEs, including serious TEAEs and TEAEs leading to discontinuation, graded by CTCAE v5.0.

    Time frame: Through study completion, an average of around 2 months.

  10. Number and percentage of participants with clinically significant abnormalities in vital signs (including pulse rate, blood pressure and heart rate).

    To assess clinically significant abnormalities in vital signs, including pulse rate, blood pressure and heart rate.

    Time frame: Through study completion, an average of around 2 months.

  11. Number and percentage of participants with clinically significant abnormalities in clinical laboratory tests (including blood chemistry, hematology, coagulation function, and urinalysis).

    To assess clinically significant abnormalities in clinical laboratory tests.

    Time frame: Through study completion, an average of around 2 months.

  12. Number and percentage of participants with clinically significant abnormalities in ECG QTc interval.

    To assess clinically significant QT/QTc abnormalities, including QTc \>450 msec, \>480 msec, \>500 msec, and increase from baseline \>60 msec.

    Time frame: Through study completion, an average of around 2 months.

  13. Number and percentage of participants with clinically significant abnormalities in other ECG parameters, including RR, PR, QRS.

    To assess clinically significant abnormalities in other ECG parameters, including RR, PR, QRS.

    Time frame: Through study completion, an average of around 2 months.

07

Study locations

1 of 1 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Nov 2026, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 22, 2026
StartActual
Oct 23, 2026
Primary completionEst.
Nov 23, 2026
CompletionEst.
Nov 23, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
Beijing Anzhen Hospital, Capital Medical University is now Recruiting
Nov 6, 2026
Start date
Oct 16, 2026→Oct 23, 2026 (actual)
Nov 6, 2026
Registered
First appeared on the registry
Oct 22, 2026
Show all 2 updates
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    Beijing Anzhen Hospital, Capital Medical University is now Recruiting
    Start date Oct 16, 2026→Oct 23, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 22, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07888569
Responsible party
Sponsor
First posted
Oct 22, 2026
Start date
Oct 23, 2026
Primary completion
Nov 23, 2026 (estimated)
Completion
Nov 23, 2026 (estimated)
Last update
Nov 6, 2026

Study contacts

Ai
Contact
Dingding.Ai@dizalpharma.com
86 021-61098344

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Birelentinib

Start the discussion